Lucine Christe

Lucine Christe

Auto-generated profile, based on publicly available information

Lucine Christe

Institute of Tissue Medicine and Pathology, University of Bern

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Science
Verified
Journal Article
Closed access
QZQiqun Zeng
Qiqun Zeng
SSSadegh Saghafinia
Sadegh Saghafinia
ACAgnieszka Chryplewicz
Agnieszka Chryplewicz
NFNadine Fournier
Nadine Fournier
LCLucine Christe
Lucine Christe
DHDouglas Hanahan
Douglas Hanahan
Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FMRP represses immune attack, as revealed by cancer cells engineered to lack its expression. FMRP-deficient tumors were infiltrated by activated T cells that impaired tumor growth and enhanced survival in mice. Mechanistically, FMRP’s immunosuppression was multifactorial, involving repression of the chemoattractant C-C motif chemokine ligand 7 (CCL7) concomitant with up-regulation of three immunomodulators—interleukin-33 (IL-33), tumor-secreted protein S (PROS1), and extracellular vesicles. Gene signatures associate FMRP’s cancer network with poor prognosis and response to therapy in cancer patients. Collectively, FMRP is implicated as a regulator that orchestrates a multifaceted barrier to antitumor immune responses.

22 March 2023 in The American Journal of Pathology
Verified
Journal Article
Open access
JLJoel-Benjamin Lincke
Joel-Benjamin Lincke
LCLucine Christe
Lucine Christe
JUJan Darius Unterlauft
Jan Darius Unterlauft
MZMartin S. Zinkernagel
Martin S. Zinkernagel
DZDenise C. Zysset-Burri
Denise C. Zysset-Burri
The gut microbiome consists of more than a thousand different microbes and their associated genes and microbial metabolites. It influences various host metabolic pathways and is therefore important for homeostasis. In recent years, its influence on health and disease has been extensively researched. In case of a microbiome disequilibrium, called dysbiosis, the gut microbiome is associated with several diseases. Consequent chronic inflammation may lead to or promote inflammatory bowel disease, obesity, diabetes mellitus, atherosclerosis, alcoholic and non-alcoholic liver disease, cirrhosis, hepatocellular carcinoma, and other diseases. The pathogenesis of the three most common retinal vascular diseases, diabetic retinopathy, retinal vein occlusion, and retinal artery occlusion, may also be influenced by an altered microbiome and associated risk factors such as diabetes mellitus, atherosclerosis, hypertension, and obesity. Direct cause-effect relationships remain less well understood. A potential prevention or treatment modality for these diseases could be targeting and modulating the individual's gut microbiome.

4 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CJCarmen Joder
Carmen Joder
AGAndrea Gmür
Andrea Gmür
WSWiebke Solaß
Wiebke Solaß
LCLucine Christe
Lucine Christe
MRManuela Rabaglio
Manuela Rabaglio
FSFranziska Siegenthaler
Franziska Siegenthaler
Lynch syndrome is an inherited tumor syndrome caused by a pathogenic germline variant in DNA mismatch repair genes. As the leading cause of hereditary endometrial cancer, international guidelines recommend universal screening in women with endometrial cancer. However, testing for Lynch syndrome is not yet well established in clinical practice. The aim of this study was to evaluate adherence to our Lynch syndrome screening algorithm. A retrospective, single-center cohort study was conducted of all endometrial cancer patients undergoing surgical treatment at the Bern University Hospital, Switzerland, between 2017 and 2022. Adherence to immunohistochemical analysis of mismatch repair status, and, if indicated, to MLH1 promoter hypermethylation and to genetic counseling and testing was assessed. Of all 331 endometrial cancer patients, 102 (30.8%) were mismatch repair-deficient and 3 (0.9%) patients were diagnosed with Lynch syndrome. Overall screening adherence was 78.2%, with a notable improvement over the six years from 61.4% to 90.6%. A major reason for non-adherence was lack of provider recommendation for testing, with advanced patient age as a potential patient risk factor. Simplification of the algorithm through standardized reflex screening was recommended to provide optimal medical care for those affected and to allow for cascading testing of at-risk relatives.

2 August 2022 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
LCLucine Christe
Lucine Christe
LVLuis Veloza
Luis Veloza
LGLouis Gros
Louis Gros
BBBettina Bisig
Bettina Bisig
SBSabine Blum
Sabine Blum
LLLaurence de Leval
Laurence de Leval

21 January 2025 in European Journal of Histochemistry
Verified
Journal Article
Open access
YMYasmeen H. Mady
Yasmeen H. Mady
CKCarmen G. Kalbermatter
Carmen G. Kalbermatter
MKMaarij Khan
Maarij Khan
ASAnna M. Schläfli
Anna M. Schläfli
RMRina Mehmeti
Rina Mehmeti
Mario P. TschanMario P. Tschan
Mario P. Tschan
Accurate differentiation of homologous proteins that share high sequence identity remains a significant challenge in biomedical research, as conventional antibodies often lack sufficient specificity, leading to potential misinterpretations. This issue is particularly evident in the study of hexokinases, a family of isoenzymes that catalyze the first step of glycolysis by phosphorylating glucose. Beyond their canonical metabolic roles, hexokinases play critical non-glycolytic functions, especially in cancer biology. However, their unique tissue distributions and context-dependent roles are often obscured by the overlapping specificities of commercially available antibodies, which can produce misleading results. In this study, we rigorously evaluated a panel of antibodies targeting hexokinase isoenzyme 3 (HK3), highlighting the widespread issue of cross-reactivity and insufficient validation. Through this process, we identified and validated a highly specific antibody for HK3, demonstrating its reliability in western blot and immunohistochemistry applications. Using this validated tool, we reveal the distinct localization of HK3 in myeloid cell populations, providing new insights into its potential functional roles in these cells. This work addresses a critical gap in antibody specificity and establishes HK3 as a uniquely expressed gene in myeloid and immune cells and is absent in other cell types under basal conditions. Providing a foundation for future investigations into its context-dependent functions.